S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way

Protagonist Therapeutics (PTGX) Earnings Date, Estimates & Call Transcripts

$20.36
-0.55 (-2.63%)
(As of 12/8/2023 ET)
Compare
Today's Range
$20.18
$20.88
50-Day Range
$14.05
$20.95
52-Week Range
$7.45
$30.10
Volume
686,119 shs
Average Volume
562,893 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.25

Earnings Summary

Upcoming
Earnings Date
Mar. 20Estimated
Actual EPS
(Nov. 2)
-$0.58 Beat By $0.10
Consensus EPS
(Nov. 2)
-$0.68
Skip Charts & View Estimated and Actual Earnings Data

PTGX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PTGX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Protagonist Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20233($1.00)($0.56)($0.76)
Q2 20232($0.81)($0.62)($0.72)
Q3 20234($0.69)($0.54)($0.64)
Q4 20234($0.69)$0.26($0.38)
FY 202313($3.19)($1.46)($2.49)
Q2 20241($0.64)($0.64)($0.64)
Q3 20241($0.72)($0.72)($0.72)

PTGX Earnings Date and Information

Protagonist Therapeutics last announced its quarterly earnings data on November 2nd, 2023. The reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.10. Protagonist Therapeutics has generated ($2.62) earnings per share over the last year (($2.62) diluted earnings per share). Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from ($1.76) to ($2.46) per share. Protagonist Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 20th, 2024 based off prior year's report dates.

Protagonist Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/20/2024
Estimated)
------- 
11/2/2023Q3 2023($0.68)($0.58)+$0.10($0.58)--
8/3/2023Q2 2023($0.65)($0.68)($0.03)($0.68)--
5/4/2023Q1 2023($0.69)($0.67)+$0.02($0.67)--
3/15/2023Q4 2022($0.67)($0.69)($0.02)($0.69)--
11/8/2022Q3 2022($0.94)($0.64)+$0.30($0.64)--
8/4/2022Q2 2022($0.99)($0.84)+$0.15($0.84)$2.30 million$0.86 million
5/4/2022Q1 2022($0.67)($0.43)+$0.24($0.43)$19.33 million$25.72 million
2/28/2022Q4 2021($0.79)($0.77)+$0.02($0.77)$7.38 million$8.62 million
11/3/2021Q3 2021($0.67)($0.70)($0.03)($0.70)$3.43 million$10.29 million
8/4/2021Q2 2021($0.55)($0.69)($0.14)($0.69)$5.60 million$2.27 million
5/4/2021Q1 2021($0.57)($0.54)+$0.03($0.54)$3.75 million$6.19 million  
3/10/2021Q4 2020($0.48)($0.48)-($0.48)$3.38 million$5.65 million  












Protagonist Therapeutics Earnings - Frequently Asked Questions

When is Protagonist Therapeutics's earnings date?

Protagonist Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 20th, 2024 based off last year's report dates. Learn more on PTGX's earnings history.

Did Protagonist Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Protagonist Therapeutics (NASDAQ:PTGX) reported ($0.58) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.68) by $0.10. Learn more on analysts' earnings estimate vs. PTGX's actual earnings.

How much revenue does Protagonist Therapeutics generate each year?

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded annual revenue of $26.58 million.

How much profit does Protagonist Therapeutics generate each year?

Protagonist Therapeutics (NASDAQ:PTGX) has a recorded net income of -$127.39 million. PTGX has generated -$2.62 earnings per share over the last four quarters.

What is Protagonist Therapeutics's EPS forecast for next year?

Protagonist Therapeutics's earnings are expected to decrease from ($1.76) per share to ($2.46) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:PTGX) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -